ArticleFrontiers in immunology2026

NLRX1 contributes to immunotherapeutic resistance of head and neck squamous cell carcinoma by suppressing type I interferon pathway.

Yuqi Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.